You have full text access to this OnlineOpen article
Relationships between the Na+/K+ pump and ATP and ADP content in mouse pancreatic islets: effects of meglitinide and glibenclamide
Article first published online: 29 JAN 2009
DOI: 10.1038/sj.bjp.0703745
2000 British Pharmacological Society
Additional Information
How to Cite
Elmi, A., Idahl, L.-Å. and Sehlin, J. (2000), Relationships between the Na+/K+ pump and ATP and ADP content in mouse pancreatic islets: effects of meglitinide and glibenclamide. British Journal of Pharmacology, 131: 1700–1706. doi: 10.1038/sj.bjp.0703745
Publication History
- Issue published online: 29 JAN 2009
- Article first published online: 29 JAN 2009
- (Received September 15, 2000, Accepted October 2, 2000)
References
- , , , , & (1998). Toward understanding the assembly and structure of KATP channels. Physiol. Rev., 78, 227–245.
- & (1998). Correlating structure and function in ATP-sensitive K+ channels. TINS, 21, 288–294.
- & (1989). Electrophysiology of the pancreatic β-cell. Prog. Biophys. Mol. Biol., 54, 87–143.
- , & (1978). Studies on the effect of tolbutamide, glibenclamide, HB 699, and glucose on serum insulin and blood glucose in gastro-enterectomized dogs. Arch. Int. Pharmacodyn., 234, 118–138.
- & (1981). Long-term effects of glibenclamide on the insulin production, oxidative metabolism and quantitative ultrastructure of mouse pancreatic islets maintained in tissue culture at different glucose concentrations. Acta Diabetol. Lat., 18, 65–83.
- & (1984). Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino)alkyl]benzoic acids. J. Med. Chem., 27, 79–81.
- , & (1998). Interplay between cytoplasmic Ca2+ and the ATP/ADP ratio: a feedback control mechanism in mouse pancreatic islets. Biochem. J., 333, 269–274.
- , & (1996). Stable and diffusible pools of nucleotides in pancreatic islet cells. Endocrinology, 137, 4671–4676.
- , , , & (1999). Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. Mol. Pharmacol., 55, 1060–1066.
- , & (1987). Interaction of diazoxide, tolbutamide and ATP4− on nucleotide-dependent K+ channels in an insulin-secreting cell line. J. Membr. Biol., 99, 215–224.
- , , , & (1981). Insulin, glucagon and somatostatin in the perfused rat pancreas and the effects of HB 699 (4-(2-(5-chloro-2-metoxy-benzamido)-ethyl)-benzoic acid). Acta Endocrinol. (Copenh), 98, 573–579.
- , , & (2000a). D-glucose stimulates the Na+/K+ pump in mouse pancreatic islet cells. Int. J. Exp. Diab. Res., 1, 155–164.
- , & (2000b). Modulation of β-cell ouabain-sensitive 86Rb+ influx (Na+/K+ pump) by D-glucose, glibenclamide or diazoxide. Int. J. Exp. Diab. Res., 1, In press.
- & (1999). β-cell ouabain-sensitive 86Rb+ influx (Na+/K+ pump): Effects of D-glucose, glibenclamide or diazoxide. Diabetologia, 42, A138.
- , , & (1996). Sulphonylureas do not increase insulin secretion by a mechanism other than a rise in cytoplasmic Ca2+ in pancreatic B-cells. Eur. J. Pharmacol., 298, 279–286.
- , , , & (1985). Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide. Diabetologia, 28, 697–703.
- , , , , , , , , & (1978). [Acylaminoalkyl substituted benzoic and phenylalkane acids with hypoglycaemic properties (author's transl)]. Arzneimittelforschung., 28, 1081–1083.
- , , & (1984). Interaction of sulfonylurea with the pancreatic B-cell. Experientia, 40, 1126–1134.
- , , , & (1974). The pancreatic β-cell recognition of insulin secretogogues. Influence of neuraminidase treatment on the release of insulin and the islet content of insulin, sialic acid, and cyclic adenosine 3′:5′- monophosphate. J. Biol. Chem., 249, 5275–5284.
- (1965). Studies in obese-hyperglycemic mice. Ann. N.Y. Acad. Sci., 131, 541–558.
- , & (1969). Adenosine triphosphate levels of mammalian pancreatic B cells after stimulation with glucose and hypoglycemic sulfonylureas. Diabetes, 18, 509–516.
- , , , & (1974). The pancreatic β-cell recognition of insulin secretagogues. Effects of calcium and sodium on glucose metabolism and insulin release. Biochem. J., 138, 33–45.
- & (1975). Effects of sulphonylurea derivatives on pancreatic β-cells. In Handbook of experimental pharmacology. ed. Hasselblatt, A. & Bruchhausen, F.V. pp. 175–194, New series, vol. XXXII/2, Berlin, Heidelberg, New York: Springer-Verlag.
- (1980). Tolbutamide stimulation and inhibition of insulin release: studies of the underlying ionic mechanisms in isolated rat islets. Diabetologia, 18, 151–160.
- (1998). A minimum of fuel is necessary for tolbutamide to mimic the effects of glucose on electrical activity in pancreatic beta-cells. Endocrinology, 139, 993–998.
- & (1982a). The electrogenic sodium-potassium pump of mouse pancreatic B-cells. J. Physiol. (Lond), 332, 529–552.
- & (1982b). Opposite effects of tolbutamide and diazoxide on 86Rb+ fluxes and membrane potential in pancreatic B cells. Biochem. Pharmacol., 31, 1407–1415.
- , , & (1980). Metabolic, cationic and secretory effects of hypoglycemic sulfonylureas in pancreatic islets. Naunyn Schmiedebergs Arch. Pharmacol., 312, 277–283.
- (1974). The preparation of, and studies on, free cell suspensions from mouse pancreatic islets. Diabetologia, 10, 431–438.
- & (1983). Mechanisms underlying the effects of 5-hydroxytryptamine and 5-hydroxytryptophan in pancreatic islets. A proposed role for L-aromatic amino acid decarboxylase. Endocrinology, 112, 1524–1529.
- & (1975). Comparison of methods for extraction of bacterial adenine nucleotides determined by firefly assay. Appl. Microbiol., 30, 713–721.
- , , & (1978). The stimulus secretion coupling of glucose-induced insulin release. XXVII. Effect of glucose on K+ fluxes in isolated islets. Pflügers Arch., 373, 237–242.
- & (1976). The kinetics of electrical activity of beta cells in response to a “square wave” stimulation with glucose or glibenclamide. Horm. Metab. Res., 8, 11–16.
- , , , & (1999). Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes. Br. J. Pharmacol., 128, 27–34.
- & (1984). The acyl-amino-alkyl benzoic acid residue and the sulfonylurea containing residue of glibenclamide affect different aspects of β-cell function. Acta Physiol. Scand., 120, 283–286.
- , , , , & (1981). Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog. Diabetologia, 20, 501–505.
- & (1988). Furosemide-induced glucose intolerance in mice is associated with reduced insulin secretion. Eur. J. Pharmacol., 147, 403–409.
- & (1974). Transport of rubidium and sodium in pancreatic islets. J. Physiol. (Lond), 242, 505–515.
- , , & (1967). Measurements of insulin activities in pancreas and serum of mice with spontaneous (“Obese” and “New Zealand Obese”) and induced (Goldthioglucose) obesity and hyperglycemia, with considerations on the pathogenesis of the spontaneous syndrome. Diabetologia, 3, 230–237.
- & (1969). Effect of insulin in vivo on diaphragm and adipose tissue of obese mice. Am. J. Physiol., 216, 98–105.
- , , & (1969). Action of some hypoglycaemic sulphonylureas on the oxygen consumption of isolated pancreatic islets of mice. Diabetologia, 5, 279–283.
- , , & (1985). The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet, 2, 474–475.
- , & (1986). Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells. Pflügers Arch., 407, 493–499.
- (1983). The effects of glibenclamide on rat islet radioactive nucleotide efflux, ATP contents and respiratory rates. Biochem. Pharmacol., 32, 2903–2908.
- & (1980). An absolute method for protein determination based on difference in absorbance at 235 and 280 nm. Anal. Biochem., 109, 156–159.
- , , , , & (1994). Positional cloning of the mouse obese gene and its human homologue [published erratum appears in Nature 1995 Mar 30;374 : 479]. Nature, 372, 425–432.
- , , , & (1988). Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells. Naunyn Schmiedebergs Arch. Pharmacol., 337, 225–230.

1476-5381/asset/olbannerleft.gif?v=1&s=198ba9e64c782a75183a18cb494f9d10ecc901ea)
1476-5381/asset/olbannerright.gif?v=1&s=0b2124237bd4227e7991f1ea05cd4bed2496a9ae)
1476-5381/asset/cover.gif?v=1&s=f56f5a76559ff1cebf2b6e329fe028f1e9e0f463)